Michael Andersson
Overview
Explore the profile of Michael Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
4888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindholm A, Abrahamsen M, Buch-Larsen K, Marina D, Andersson M, Helge J, et al.
Breast Cancer Res
. 2024 Oct;
26(1):142.
PMID: 39415181
Background: Breast cancer patients have an increased risk of cardiometabolic disease and for many patients, adjuvant therapy causes an altered lipid profile, insulin resistance and inflammation. Previous follow-up studies are...
2.
Marina D, Buch-Larsen K, Gillberg L, Andersen M, Andersson M, Rasmussen A, et al.
Cancer Med
. 2024 Aug;
13(15):e70015.
PMID: 39108148
Objective: Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer (EBC). Among others, weight gain is one of the observed side effects of both chemotherapy and other...
3.
Buch-Larsen K, Gillberg L, Ahmed H, Marstrand S, Andersson M, van Hall G, et al.
Nutrition
. 2024 Mar;
122:112394.
PMID: 38458062
Background: Breast cancer survivors are a growing population due to improved treatment. It is known that postmenopausal women treated for breast cancer may experience weight gain and increased insulin resistance,...
4.
Bager Christensen I, Abrahamsen M, Ribas L, Buch-Larsen K, Marina D, Andersson M, et al.
Cancer Med
. 2023 Jul;
12(16):16985-16996.
PMID: 37439084
Background: Adjuvant chemo- and radiotherapy cause cellular damage to tumorous and healthy dividing cells. Chemotherapy has been shown to cause mitochondrial respiratory dysfunction in non-tumorous tissues, but the effects on...
5.
Artzi D, Berg T, Celik A, Kumler I, Kenholm J, Al-Rawi S, et al.
Acta Oncol
. 2023 Jun;
62(6):601-607.
PMID: 37338513
Background: The purpose was to investigate the treatment flow of patients with HER2-positive metastatic breast cancer (mBC), progression-free survival (PFS) and overall survival (OS) across treatment lines and adherence to...
6.
Kolcsar L, Oosterbroek P, Gavryushin D, Olsen K, Paramonov N, Pilipenko V, et al.
Biodivers Data J
. 2023 Feb;
9:e67085.
PMID: 36761998
Background: Limoniidae is one of the most species-rich Dipteran families, with 661 reported species in Europe. Despite the fact that the European limoniid crane fly fauna has been studied ever...
7.
Marina D, Rasmussen A, Buch-Larsen K, Gillberg L, Andersson M, Schwarz P
Cancer Med
. 2022 Jun;
12(2):967-982.
PMID: 35748065
Introduction: Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are...
8.
Pedersen J, Strandberg-Larsen K, Andersson M, Hansen J
Am J Ind Med
. 2022 May;
65(8):660-668.
PMID: 35615993
Background: Organic solvents have been suggested to increase the risk of breast cancer although the epidemiologic evidence is limited. This study explored the association between organic solvents and breast cancer....
9.
Celik A, Berg T, Nielsen L, Jensen M, Ejlertsen B, Knoop A, et al.
Breast Cancer (Auckl)
. 2022 Apr;
16:11782234221086992.
PMID: 35359608
Purpose: Dual blockade with trastuzumab and pertuzumab in combination with chemotherapy is the recommended first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). The purpose...
10.
Jakobsen M, Kolodziejczyk C, Jensen M, Bo Poulsen P, Khan H, Kumler T, et al.
BMC Cancer
. 2021 Sep;
21(1):1040.
PMID: 34537007
Background: There is increasing concern about cardiovascular disease (CVD) after breast cancer (BC). The aim of this study was to estimate the prevalence of different types of CVD in women...